ECSP23095674A - Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) - Google Patents
Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)Info
- Publication number
- ECSP23095674A ECSP23095674A ECSENADI202395674A ECDI202395674A ECSP23095674A EC SP23095674 A ECSP23095674 A EC SP23095674A EC SENADI202395674 A ECSENADI202395674 A EC SENADI202395674A EC DI202395674 A ECDI202395674 A EC DI202395674A EC SP23095674 A ECSP23095674 A EC SP23095674A
- Authority
- EC
- Ecuador
- Prior art keywords
- wrn
- inhibition
- treatment
- diseases related
- pyrimidine analogs
- Prior art date
Links
- 201000011032 Werner Syndrome Diseases 0.000 title 2
- 102000019196 RecQ Helicases Human genes 0.000 title 1
- 108010012737 RecQ Helicases Proteins 0.000 title 1
- -1 TRIAZOLE PYRIMIDINE ANALOGS Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (I): (I) en donde R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K y A han sido descriptos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos para elaborar los compuestos de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021096104 | 2021-05-26 | ||
| CN2022085537 | 2022-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23095674A true ECSP23095674A (es) | 2024-01-31 |
Family
ID=82019774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202395674A ECSP23095674A (es) | 2021-05-26 | 2023-12-21 | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11878973B2 (es) |
| EP (1) | EP4347596A1 (es) |
| JP (2) | JP7753397B2 (es) |
| KR (1) | KR20240013168A (es) |
| CN (1) | CN117425657A (es) |
| AR (1) | AR125966A1 (es) |
| AU (1) | AU2022279728A1 (es) |
| BR (1) | BR112023024551A2 (es) |
| CA (1) | CA3219799A1 (es) |
| CL (1) | CL2023003489A1 (es) |
| CO (1) | CO2023018119A2 (es) |
| CR (1) | CR20230616A (es) |
| DO (1) | DOP2023000256A (es) |
| EC (1) | ECSP23095674A (es) |
| IL (1) | IL308229A (es) |
| JO (1) | JOP20230304A1 (es) |
| MX (1) | MX2023013892A (es) |
| PE (1) | PE20240587A1 (es) |
| PH (1) | PH12023553140A1 (es) |
| PY (1) | PY2240956A (es) |
| TW (1) | TW202313616A (es) |
| UY (1) | UY39786A (es) |
| WO (1) | WO2022249060A1 (es) |
| ZA (1) | ZA202310237B (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241802A2 (en) * | 2018-06-15 | 2019-12-19 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| UY40470A (es) * | 2022-10-12 | 2024-05-15 | Novartis Ag | Compuestos tricíclicos y sus usos |
| JP2025539085A (ja) * | 2022-11-16 | 2025-12-03 | ノバルティス アーゲー | 二環式複素環及びｗｒｎ阻害剤としてのその使用 |
| TW202421158A (zh) | 2022-11-18 | 2024-06-01 | 瑞士商諾華公司 | 藥物組合及其用途 |
| CN120225526A (zh) | 2022-11-23 | 2025-06-27 | 诺华股份有限公司 | 用于治疗癌症的稠合吡啶的固体形式 |
| JP2025540756A (ja) * | 2022-12-05 | 2025-12-16 | 江蘇恒瑞医薬股▲ふん▼有限公司 | トリアゾール化合物、その製造方法と医薬的用途 |
| TW202425970A (zh) | 2022-12-30 | 2024-07-01 | 大陸商蘇州浦合醫藥科技有限公司 | Wrn抑制劑 |
| WO2024140597A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Wrn解旋酶抑制剂 |
| CN120603834A (zh) * | 2023-01-18 | 2025-09-05 | 成都微芯药业有限公司 | 双杂环wrn抑制剂、其制备方法及其应用 |
| WO2024155884A1 (en) * | 2023-01-20 | 2024-07-25 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as wrn inhibitors |
| WO2024153244A1 (zh) * | 2023-01-20 | 2024-07-25 | 南京再明医药有限公司 | 含氮类化合物 |
| WO2024187049A1 (en) * | 2023-03-08 | 2024-09-12 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as wrn inhibitors |
| WO2024193716A1 (zh) * | 2023-03-17 | 2024-09-26 | 南京再明医药有限公司 | 三唑并嘧啶类化合物 |
| CN120858096A (zh) * | 2023-03-23 | 2025-10-28 | 北京丹擎医药科技有限公司 | 双环衍生物及其组合物和应用 |
| EP4692088A1 (en) | 2023-03-24 | 2026-02-11 | Shanghai Jeyou Pharmaceutical Co., Ltd. | Compound acting as wrn helicase inhibitor |
| TW202438062A (zh) * | 2023-03-24 | 2024-10-01 | 大陸商上海濟煜醫藥科技有限公司 | 作爲wrn解旋酶抑制劑的雜環類化合物及其製備方法和應用 |
| WO2024220887A1 (en) * | 2023-04-21 | 2024-10-24 | Nimbus Wadjet, Inc. | [1,2,4]triazolo[1,5-a]pyrimidinone wrn inhibitors |
| CN120981458A (zh) * | 2023-04-25 | 2025-11-18 | 苏州浦合医药科技有限公司 | Wrn抑制剂 |
| CN116496223A (zh) * | 2023-04-26 | 2023-07-28 | 福建凯昕药业有限公司 | 5-溴-4-甲基-2-三氟甲基嘧啶的一种制备方法 |
| WO2024230828A1 (en) * | 2023-05-11 | 2024-11-14 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| CN121127473A (zh) * | 2023-05-17 | 2025-12-12 | 英矽智能科技知识产权有限公司 | 作为wrn抑制剂的螺环衍生物 |
| TW202510857A (zh) * | 2023-06-01 | 2025-03-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 化合物及其用途 |
| EP4724070A2 (en) | 2023-06-08 | 2026-04-15 | Nimbus Wadjet, Inc. | Wrn inhibitors |
| WO2024254602A1 (en) * | 2023-06-09 | 2024-12-12 | Nimbus Wadjet, Inc. | Oxazolopyridin-7(4h)-one wrn inhibitors |
| CN121358739A (zh) * | 2023-06-12 | 2026-01-16 | 抟相医药(上海)有限公司 | 新型化合物，包含其的组合物及其用途 |
| WO2024259048A2 (en) * | 2023-06-13 | 2024-12-19 | Nimbus Wadjet, Inc. | Thiazolopyridin-7(4h)-one wrn inhibitors |
| WO2024255790A1 (zh) * | 2023-06-15 | 2024-12-19 | 勤浩医药（苏州）有限公司 | 稠环化合物、包含其的药物组合物及其用途 |
| TW202506111A (zh) * | 2023-07-07 | 2025-02-16 | 美商林伯士瓦吉特公司 | 三唑并wrn抑制劑 |
| WO2025014846A1 (en) * | 2023-07-11 | 2025-01-16 | Merck Sharp & Dohme Llc | Spirocyclic wrn helicase inhibitors |
| WO2025021148A1 (zh) * | 2023-07-27 | 2025-01-30 | 贝达药业股份有限公司 | Wrn抑制剂及其药物组合物和应用 |
| WO2025026382A1 (zh) * | 2023-08-01 | 2025-02-06 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025040168A1 (en) * | 2023-08-24 | 2025-02-27 | Zai Lab (Shanghai) Co., Ltd. | Spiro-triazolopyrimidine analogues as wrn inhibitors and uses thereof |
| CN119528909A (zh) * | 2023-08-29 | 2025-02-28 | 上海科恩泰生物医药科技有限公司 | 一种抑制wrn解旋酶的双杂环衍生物、含其的药物组合物及其应用 |
| AU2024332123A1 (en) * | 2023-08-29 | 2026-02-26 | Eikon Therapeutics, Inc. | Compositions comprising werner syndrome helicase inhibitors and methods of using the same |
| TW202515558A (zh) * | 2023-09-08 | 2025-04-16 | 美商Ｍｏｍａ治療公司 | 三環衍生物及相關用途 |
| WO2025067429A1 (en) * | 2023-09-28 | 2025-04-03 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025073792A1 (en) | 2023-10-02 | 2025-04-10 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| CN121646596A (zh) * | 2023-10-12 | 2026-03-10 | 楚浦创制（武汉）医药科技有限公司 | 吡啶酮并环类衍生物及其应用 |
| WO2025087274A1 (zh) * | 2023-10-27 | 2025-05-01 | 浙江海正药业股份有限公司 | 氮杂双环类衍生物及其制备方法和用途 |
| WO2025106949A1 (en) * | 2023-11-16 | 2025-05-22 | Radd Pharmaceuticals, Inc. | Wrn inhibitors |
| WO2025106693A1 (en) * | 2023-11-16 | 2025-05-22 | Eikon Therapeutics, Inc. | Methods and compositions for treating cancers with high microsatellite instability levels |
| CN117865963B (zh) * | 2023-12-15 | 2026-02-24 | 上海凌凯科技股份有限公司 | 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物 |
| WO2025130971A1 (zh) * | 2023-12-21 | 2025-06-26 | 勤浩医药（苏州）有限公司 | 稠环化合物、包含其的药物组合物及其用途 |
| US20250206738A1 (en) * | 2023-12-21 | 2025-06-26 | Nimbus Wadjet, Inc. | Wrn inhibitors |
| WO2025133395A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Bicyclic (hetero)arylene wrn inhibitory compounds |
| WO2025137640A1 (en) * | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| TW202542158A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 稠環化合物、包含其的藥物組合物及其用途 |
| WO2025152932A1 (zh) * | 2024-01-15 | 2025-07-24 | 上海齐鲁制药研究中心有限公司 | 一种三唑并嘧啶类衍生物、其制备方法和应用 |
| WO2025152750A1 (zh) * | 2024-01-17 | 2025-07-24 | 成都微芯药业有限公司 | 双杂环wrn抑制剂、其制备方法及其应用 |
| CN120398919B (zh) * | 2024-02-01 | 2026-04-07 | 福石生物科技(合肥)有限公司 | 作为wrn抑制剂的螺环衍生物及其应用 |
| CN120424093A (zh) * | 2024-02-02 | 2025-08-05 | 中国科学院上海药物研究所 | 螺环类化合物、包含其的药物组合物及其用途 |
| WO2025162478A1 (en) * | 2024-02-04 | 2025-08-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025172934A1 (en) | 2024-02-16 | 2025-08-21 | Janssen Pharmaceutica Nv | Triazolo[4,5-b]pyridine compounds useful as inhibitors of werner syndrome recq helicase (wrn) |
| WO2025180452A1 (zh) * | 2024-02-29 | 2025-09-04 | 南京再明医药有限公司 | Wrn抑制剂化合物及其应用 |
| WO2025191176A1 (en) | 2024-03-14 | 2025-09-18 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2025223396A1 (en) * | 2024-04-22 | 2025-10-30 | 3H Pharmaceuticals Co., Ltd. | Fused tricyclic compounds and methods of use thereof |
| WO2025223388A1 (zh) * | 2024-04-22 | 2025-10-30 | 南京再明医药有限公司 | 三并环类化合物及其应用 |
| WO2025232693A1 (en) * | 2024-05-08 | 2025-11-13 | Nuphase Therapeutics (Shanghai) Limited., Co. | Novel compounds, compositions comprising the same and uses thereof |
| WO2025237361A1 (zh) * | 2024-05-16 | 2025-11-20 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025250620A1 (en) * | 2024-05-28 | 2025-12-04 | Nimbus Wadjet, Inc. | Tricyclic fused wrn inhibitors |
| WO2025252190A1 (en) * | 2024-06-07 | 2025-12-11 | Cullgen Inc. | Targeted degraders of werner syndrome recq helicase |
| WO2025261355A1 (en) * | 2024-06-20 | 2025-12-26 | Insilico Medicine Ip Limited | Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof |
| WO2025261486A1 (en) * | 2024-06-22 | 2025-12-26 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2026006796A1 (en) * | 2024-06-27 | 2026-01-02 | Eikon Therapeutics, Inc. | Compositions comprising werner syndrome helicase inhibitors and methods of using the same |
| WO2026002176A1 (zh) * | 2024-06-28 | 2026-01-02 | 武汉人福创新药物研发中心有限公司 | 作为wrn抑制剂的含芳香环化合物及其应用 |
| WO2026003380A1 (en) | 2024-06-28 | 2026-01-02 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| CN121426817A (zh) * | 2024-07-10 | 2026-01-30 | 广州科恩泰生物医药科技有限公司 | 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用 |
| WO2026028180A1 (en) | 2024-08-01 | 2026-02-05 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7(4h)-one derivatives useful as inhibitors of wrn |
| WO2026028179A1 (en) | 2024-08-01 | 2026-02-05 | Janssen Pharmaceutica Nv | Compounds useful as inhibitors of werner syndrome recq helicase (wrn) |
| WO2026039591A1 (en) * | 2024-08-15 | 2026-02-19 | Synnovation Therapeutics, Inc. | Compounds comprising a fused tetracyclic group useful as wrn inhibitors |
| CN119431379B (zh) * | 2024-11-06 | 2026-04-24 | 中国药科大学 | Wrn降解剂及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP2010502644A (ja) | 2006-08-29 | 2010-01-28 | トラスティーズ オブ ボストン ユニバーシティ | Ｗｒｎ結合分子を用いる治療方法 |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| WO2014133112A1 (ja) * | 2013-03-01 | 2014-09-04 | 国立大学法人東京大学 | オートタキシン阻害活性を有する８－置換イミダゾピリミジノン誘導体 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| MX2020013120A (es) * | 2018-06-04 | 2021-07-21 | Broad Inst Inc | Tratamiento terapéutico de cánceres de microsatélites inestables. |
| WO2019241802A2 (en) | 2018-06-15 | 2019-12-19 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| WO2020041756A1 (en) | 2018-08-23 | 2020-02-27 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CN112778311B (zh) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
| WO2022076403A1 (en) | 2020-10-05 | 2022-04-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Helicase inhibitors for treatment of medical disorders |
-
2022
- 2022-05-24 JP JP2023572685A patent/JP7753397B2/ja active Active
- 2022-05-24 BR BR112023024551A patent/BR112023024551A2/pt unknown
- 2022-05-24 CN CN202280035572.6A patent/CN117425657A/zh active Pending
- 2022-05-24 AR ARP220101380A patent/AR125966A1/es unknown
- 2022-05-24 WO PCT/IB2022/054850 patent/WO2022249060A1/en not_active Ceased
- 2022-05-24 AU AU2022279728A patent/AU2022279728A1/en active Pending
- 2022-05-24 KR KR1020237044267A patent/KR20240013168A/ko active Pending
- 2022-05-24 MX MX2023013892A patent/MX2023013892A/es unknown
- 2022-05-24 EP EP22729790.0A patent/EP4347596A1/en active Pending
- 2022-05-24 TW TW111119316A patent/TW202313616A/zh unknown
- 2022-05-24 UY UY0001039786A patent/UY39786A/es unknown
- 2022-05-24 PE PE2023003130A patent/PE20240587A1/es unknown
- 2022-05-24 PH PH1/2023/553140A patent/PH12023553140A1/en unknown
- 2022-05-24 PY PY202202240956A patent/PY2240956A/es unknown
- 2022-05-24 IL IL308229A patent/IL308229A/en unknown
- 2022-05-24 CA CA3219799A patent/CA3219799A1/en active Pending
- 2022-05-24 CR CR20230616A patent/CR20230616A/es unknown
- 2022-05-25 US US17/824,407 patent/US11878973B2/en active Active
-
2023
- 2023-11-02 ZA ZA2023/10237A patent/ZA202310237B/en unknown
- 2023-11-10 US US18/506,164 patent/US20240360118A1/en active Pending
- 2023-11-22 DO DO2023000256A patent/DOP2023000256A/es unknown
- 2023-11-23 JO JOJO/P/2023/0304A patent/JOP20230304A1/ar unknown
- 2023-11-23 CL CL2023003489A patent/CL2023003489A1/es unknown
- 2023-12-21 EC ECSENADI202395674A patent/ECSP23095674A/es unknown
- 2023-12-21 CO CONC2023/0018119A patent/CO2023018119A2/es unknown
-
2025
- 2025-10-01 JP JP2025165245A patent/JP2026021315A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL308229A (en) | 2024-01-01 |
| TW202313616A (zh) | 2023-04-01 |
| BR112023024551A2 (pt) | 2024-02-15 |
| JOP20230304A1 (ar) | 2023-11-23 |
| CN117425657A (zh) | 2024-01-19 |
| JP7753397B2 (ja) | 2025-10-14 |
| CO2023018119A2 (es) | 2023-12-29 |
| US20240360118A1 (en) | 2024-10-31 |
| US20230046859A1 (en) | 2023-02-16 |
| AU2022279728A1 (en) | 2023-11-16 |
| PH12023553140A1 (en) | 2024-04-29 |
| AR125966A1 (es) | 2023-08-30 |
| CR20230616A (es) | 2024-05-06 |
| UY39786A (es) | 2023-01-31 |
| MX2023013892A (es) | 2023-12-11 |
| WO2022249060A1 (en) | 2022-12-01 |
| DOP2023000256A (es) | 2024-01-31 |
| KR20240013168A (ko) | 2024-01-30 |
| US11878973B2 (en) | 2024-01-23 |
| JP2024522345A (ja) | 2024-06-18 |
| PY2240956A (es) | 2023-11-09 |
| JP2026021315A (ja) | 2026-02-10 |
| ZA202310237B (en) | 2025-02-26 |
| CL2023003489A1 (es) | 2024-06-28 |
| PE20240587A1 (es) | 2024-03-21 |
| CA3219799A1 (en) | 2022-12-01 |
| EP4347596A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23095674A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| CL2025001072A1 (es) | Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| ECSP16067921A (es) | Derivados de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| ECSP20080991A (es) | Compuestos de cianotriazol y usos de los mismos | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| AR124189A1 (es) | Compuestos y procedimientos de uso de los mismos | |
| AR128109A1 (es) | Spiros y análogos relacionados para inhibir yap / taz-tead | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
| AR134040A1 (es) | Moduladores de mrgprx2 y métodos de tratamiento relacionados | |
| PY2189412A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis | |
| ECSP22030740A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR120158A2 (es) | Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue | |
| CO2025005872A2 (es) | Compuestos tricíclicos y sus usos | |
| AR133249A1 (es) | Nuevos compuestos | |
| MX2025008259A (es) | Inhibidores de prmt5-mta |